eXoZymes, Inc.

NASDAQ:EXOZ

Biotechnology

Healthcare
$5.54 +16.75%

+$1.06 today

Market cap
$51.42M
Beta
2.66
P/E (TTM)
-6.5
EPS (TTM)
-$1.14
52W Low $6.33High $18.40

Volume 0.01M

Average 0.01M

Returns on capital

eXoZymes, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-269.6%

avg 0.4%

ROIC

-203.1%

avg -101.4%

ROA

-153.4%

avg -71.8%

Analysis

ROA is currently the strongest return metric at -153.4% versus its period average of -71.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Michael Heltzen

President & Chief Executive OfficerUSD 608.33K4514.45K0.17%

Damien A. Perriman

Chief Commercial OfficerUSD 310.76K49——

Tyler Korman

Co-Founder & Chief Scientific OfficerUSD 260.42K47——

Fouad Nawaz

Vice President of FinanceUSD 258.33K4045.00K0.53%

Paul Opgenorth

Co-Founder & Vice President of DevelopmentUSD 257.29K43——

James U. Bowie

Founder & Independent Director—64——

Lasse H. Gorlitz

Vice President of Communications————

Michael Burns

Executive Vice President of Energy Transition————

Amy Lunzer

Chief of Staff————

Compensation is shown in the reported currency; data updated Sep 19, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 14, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

5

$6,405.17

Sells

2

$15,424.20

Net Transaction Value

−$9,019.03

Net selling

Most Active

Heltzen Michael

5 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Aug 26, 26

Heltzen Michael

Direct

Buy$30.3
Aug 26, 26

Heltzen Michael

Direct

Buy$1.8K
Aug 26, 26

Heltzen Michael

Direct

Buy$1.9K
Aug 25, 26

Heltzen Michael

Direct

Buy$1.9K
Aug 25, 26

Heltzen Michael

Direct

Buy$750
Apr 9, 26

Korman Tyler Paz

Direct

Sell$7.9K
Apr 8, 26

Korman Tyler Paz

Direct

Sell$7.5K

Summary

Insiders reported 5 buys worth $6,405.17 and 2 sells worth $15,424.20 over the last 12 months. That adds up to net selling of $9,019.03. Heltzen Michael was the most active insider with 5 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A —
RevenueN/AN/AN/A
N/A —
Net IncomeN/AN/AN/A
N/A —
EBITN/AN/AN/A
N/A —

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Competitors

Who does eXoZymes, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about EXOZ's management, answered from reported figures.

Who manages EXOZ?

eXoZymes, Inc. (EXOZ) lists 9 active executives. The top listed executive is Paul Opgenorth, Co-Founder & Vice President of Development.

Are EXOZ insiders buying or selling?

Recent insider activity shows net buying of $4.98M.